dexamethasone

Org: Université de Poitiers et Centre Hospitalier Universitaire de Poitiers, INSERM U1313 and CIC 1082, Poitiers, France, Hôpital Haut Leveque, University Hospital, Pessac, France, ECSTRA, Centre de Recherche en Epidémiologie et Statistiques, INSERM UMR 1153, Paris, France, Lille University Hospital, Lille, France, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France,

Abstract

Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).

Org: Centre Hospitalier Universitaire de Nantes, Ankara University, University of Athens, School of Medicine, Showa University, Memorial Sloan Kettering Cancer Center,

Abstract

DIET2TREAT: A randomized, multi-center, phase 2 trial of a ketogenic diet vs standard dietary guidance in combination with standard-of-care treatment for patients with newly diagnosed glioblastoma.

Org: Providence Saint John’s Health Center, Santa Monica, CA, Milwaukee, WI, Cedars-Sinai Cancer,

Clinical trial

A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy

Status: , Estimated PCD: 2021-12-01

Abstract

Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).

Org: Princess Margaret Cancer Centre, Ankara University, University Hospital Brno, General Hospital Evangelismos, Athens, Greece, St. Vincent's Hospital Melbourne,

Abstract

Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.

Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,

Abstract

All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D.

Org: Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Poitiers, Vendée Departmental Hospital Centre, Hopital Cote de Nacre, Hematology Department, University Cancer Institute IUCT oncopôle, Toulouse, France,

Abstract

Ambulatory teclistamab administration in patients with relapsed/refractory multiple myeloma.

Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University,

Abstract

Randomized phase IIb trial of a CMV vaccine immunotherapeutic candidate (VBI-1901) in recurrent glioblastomas.

Org: Dana-Farber Cancer Institute and Harvard Medical School,

Abstract

Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.

Org: Lehigh Valley Health Network, University of Oklahoma, Stephenson Cancer Center, H. Lee Moffitt Cancer Center at Memorial Healthcare System, Stony Brook University Medical Center,

Abstract

Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4).

Org: School of Public Health & Preventative Medicine, Monash University, Melbourne, Australia, Hospital Universitario Doctor Peset, Valencia, Spain, Hospital Virgen de las Nieves, Granada, Spain, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Australia, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea,

Abstract

Post-ASCT consolidation with EPD or ERD in patients with high-risk multiple myeloma.

Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,

Abstract

CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA: Phase 3 MK-5684-004 study.

Org: Roanoke, University Hospital Freiburg,

Abstract

Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Org: Universitair Ziekenhuis Gent, Health Research Institute IIS-FJD, Lymphoma Service, Memorial Sloan Kettering Cancer Center,

Abstract

A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.

Org: Boston University Section of Hematology and Medical Oncology,

Abstract

Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM).

Org: NIHR UCLH Clinical Research Facility, Department of Clinical Haematology,

Abstract

Frontline treatment with zanubrutinib plus rituximab (ZR) followed by short course R-DHAOx in patients with mantle cell lymphoma (MCL): Results of the phase II CHESS clinical trial.

Org: Department of Hematology, Huizhou Municipal Central Hospital, Department of Medical Oncology, The Second Hospital of Dalian Medical University, Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University,

Abstract

Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without plasmapheresis.

Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA,

Abstract

Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire.

Org: Health Data Specialists,

Abstract

Real-world comparison: Neoadjuvant pembrolizumab (pembro-NACT) vs. dose-dense neoadjuvant chemotherapy (ddNACT) in early stage triple-negative breast cancer (TNBC).

Org: Zucker School of Medicine,

Clinical trial

Effect of Perineural Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Ankle Surgery

Status: Completed, Estimated PCD: 2023-11-21

Abstract

Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial.

Org: The University of Texas MD Anderson Cancer Center, Houston, TX, USA,

Abstract

Prevention of pemetrexed-induced rash with low-dose dexamethasone in patients with NSCLC receiving immunotherapy: A prospective, single-arm clinical trial.

Org: Department of Oncology, the Second People's Hospital of Yibin, Yibin, China, Department of Oncology, the Second People's Hospital of Yibin, Yibin, SIchuan, China, Department of Oncology,the Second People's Hospital of Yibin City, Yibin, China,

Abstract

CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: Phase 3 MK-5684-003 trial.

Org: Fred Hutchinson Cancer Center, University of Washington and Fred Hutchinson Cancer Research Centre, Merck & Co., Inc., Rahway, NJ, University of Minnesota Masonic Cancer Center, Minneapolis, MN,

Abstract

Effect of daratumumab on light chain reduction in newly diagnosed multiple myeloma with light chain cast nephropathy.

Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC,

Abstract

Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM).

Org: Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Froedtert & Medical College of Wisconsin Cancer Center,

Abstract

Efficacy of carfilzomib-based regimens as induction/consolidation therapy in newly diagnosed multiple myeloma: A meta-analysis.

Org: Albany Medical Center Hospital, JT Mather/Northwell Health,

Abstract

Analysis of real-world (RW) pomalidomide (pom) dosing patterns in patients (pts) with multiple myeloma (MM) from the Flatiron database.

Org: Myeloma, Waldenstrom’s and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy,

Abstract

High-dose furmonertinib in combination with intraventricular chemotherapy for EGFR exon 20 insertion mutated lung adenocarcinoma with leptomeningeal metastasis.

Org: Nanjing Chest Hospital, Nanjing Gaochun People's Hospital,

Abstract

Metabolic changes due to dexamethasone premedication in patients with breast cancer.

Org: ICESP,

Abstract

Final results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM).

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, GlaxoSmithKline,

Clinical trial

Iontophoresis With Dexamethasone in Combination With Physical Therapy for the Treatment of Pediatric Patients Diagnosed With Apophysitis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial

Status: Terminated, Estimated PCD: 2021-12-22

Clinical trial

A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Status: Recruiting, Estimated PCD: 2024-07-01

Clinical trial

Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma

Status: Completed, Estimated PCD: 2016-05-18

Clinical trial

A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan, and Dexamethasone (V-MD) in Patients With Symptomatic AL-Amyloidosis or Light Chain Deposition Disease

Status: Completed, Estimated PCD: 2010-10-01

Clinical trial

Effect of Continuous Paravertebral Nerve Block Combined With Dexamethasone Palpitate vs Combined With Dexamethasone Sodium Phosphate on Chronic Postoperative Pain in Patients Undergoing Minimally Invasive Cardiac Surgery

Status: Recruiting, Estimated PCD: 2024-09-30

Clinical trial

An Early Combined Microbiota and Metabolic Signature in Ulcerative Colitis Patients Predict the Clinical Success of Anti-inflammatory Therapy

Status: Recruiting, Estimated PCD: 2025-01-31

Clinical trial

Effect of Perioperative Intravenous Dexamethasone Administration in Patients Undergoing Total Shoulder Arthroplasty for Osteoarthritis, in Terms of Post-operative Pain, Function, Nausea, Hospitalization Length, and Risk of Complications

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

Comparison of Cervical Transforaminal Epidural Corticosteroid Injections With Lateralized Interlaminar Epidural Corticosteroid Injections for Treatment of Cervicogenic Upper Extremity Radiculopathy

Status: Completed, Estimated PCD: 2023-07-16

Clinical trial

Optimal Multimodal Pain Management Package Versus Regular Bottled Pain Formulation for Outpatient Use Following Microdiscectomies , Foraminotomies, and Spinal Decompressions: A Randomized Control Trial Comparing Two Strategies

Status: Not yet recruiting, Estimated PCD: 2025-06-01

Clinical trial

Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL)

Status: Terminated, Estimated PCD: 2022-07-28

Clinical trial

A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Best Systemic Chemotherapy

Status: Active (not recruiting), Estimated PCD: 2025-05-01

Clinical trial

Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease

Status: Terminated, Estimated PCD: 2018-10-31

Clinical trial

Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia

Status: Completed, Estimated PCD: 2010-09-01

Clinical trial

Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission

Status: , Estimated PCD: 2006-12-01

Clinical trial

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study

Status: Active (not recruiting), Estimated PCD: 2024-09-01

Clinical trial

Towards a Self-Administered Hearing Protection Regimen

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies

Status: , Estimated PCD: 2016-03-01

Clinical trial

A Phase II Study of Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

Status: Active (not recruiting), Estimated PCD: 2025-05-01

Clinical trial

Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy

Status: Active (not recruiting), Estimated PCD: 2018-04-01

Clinical trial

A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin As Adjuvant Treatment After Resection Of Hepatic Metastases From Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

Study Of Epoetin Alfa Vs Epoetin Alfa With Dexamethasone In Hormone Refractory Prostate Cancer Patients: Impact On Fatigue, Anemia, Functional Status And Quality Of Life

Status: , Estimated PCD: 2006-06-01

Clinical trial

A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA

Status: , Estimated PCD: 2003-04-01

Clinical trial

A Phase III Study of Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Status: Active (not recruiting), Estimated PCD: 2025-03-31

Clinical trial

The Randomized Clinical Trials of Letrozole Administration During Luteal Phase in Patients Who Have the Risk of Ovarian Hyperstimulation Syndrome

Status: Not yet recruiting, Estimated PCD: 2024-03-01

Clinical trial

A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol

Status: Active (not recruiting), Estimated PCD: 2024-01-01

Abstract

First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.

Org: University College London Cancer Institute, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Medical College of Wisconsin, Peter MacCallum Cancer Centre, Melbourne, Australia, Hematology Clinic,

Abstract

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.

Org: Schleswig-Holstein University Hospital, Hospital Salzburg Paracelus University, University Hospital rechts der Isar, Jena University Hospital, Wuerzburg University Medical Center,

Abstract

Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in.

Org: Winship Cancer Center of Emory University, Emory University, Atlanta, GA, USA, Emory University School of Medicine, Biostatistics Shared Resource, Winship Cancer Institute of Emory University,

Abstract

Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).

Org: University of California Irvine, University of California San Diego, University of California Irvine Department of Epidemiology and Biostatistics, Norton Cancer Institute, Rutgers Cancer Center,

Abstract

A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9.

Org: Memorial Sloan Kettering Cancer Center, Katedra i Klinika Hematoonkologii i Transplantacji Szpiku, Seoul National University Hospital, Hospital Quirón Madrid, University of Kansas Medical Center, Department of Biostatistics & Data Science,

Abstract

Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data.

Org: Samuel Oschin Comprehensive Cancer Center, Department of Hematology, Mayo Clinic Rochester, Janssen Global Market Access, Janssen Scientific Affairs, Georgetown University Medical Center,

Abstract

Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.

Org: Carolina Urologic Research Center, Oncology Hematology Consultants Ltd., First Urology, Urology Cancer Center, PC, National Cancer Institute, Vilnius, Lithuania,

Abstract

A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.

Org: Dana-Farber Cancer Institute, Bristol Myers Squibb, Institute for Myeloma and Bone Cancer Research, Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Catalan Institute of Oncology and Josep Carreras Institute,

Abstract

Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).

Org: Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, The Wistar Institute, Active Biotech,

Abstract

MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Org: Centre Hospitalier Universitaire de Nantes, Clinica São Germano, São Paulo, Brazil, Columbia University Medical Center, Sylvester Comprehensive Cancer Center, Miami, FL, Janssen Research & Development,

Abstract

OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.

Org: Anaveon, Institute of Medical Oncology, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Lillebaelt Hospital, University Hospital of Southern Denmark,

Abstract

Identification of genes encoding targets associated with adverse events in multiple myeloma.

Org: Kansas State University–Olathe, Taussig Cancer Center, Cleveland Clinic Taussig Cancer Instititute, University of Missouri Kansas City, Indiana University/Melvin and Bren Simon Cancer Center,

Abstract

Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).

Org: MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, U T MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study.

Abstract

Physical and emotional quality of life in children with B-acute lymphoblastic leukemia randomized to every 4- vs. 12-week vincristine/dexamethasone during maintenance: Children’s Oncology Group AALL0932.

Org: Children's Oncology Group Data Center, Yale University Hematology/Oncology, St. Jude Children's Research Hospital, Children's National Medical Center, Washington, DC, University of Texas Southwestern Medical Center,

Abstract

Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.

Org: Roswell Park Comprehensive Cancer Center, IU Simon Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center,

Abstract

EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Org: Winship Cancer Center of Emory University, St. Vincent’s Hospital, University of Melbourne, National and Kapodistrian University of Athens, Clínica Universidad de Navarra and CIBEREHD,

Abstract

A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency.

Org: Emory University School of Medicine and Winship Cancer Institute, UPMC Cancer Center - Hillman Cancer Center, Winship Cancer Institute of Emory University,

Abstract

Prevention of amivantamab infusion related reactions with extended pre-infusion day oral steroid therapy.

Org: Icon Cancer Centre, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center,

Abstract

Treatments and outcomes of patients with localized extranodal NK/T-cell lymphoma (ENKL) diagnosed between 2014 and 2021: A cooperative study in Japan.

Org: Mie University Graduate School of Medicine, Tsu, Japan, Shimane University Hospital, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Nagano Prefectural Shinshu Medical Center, National Cancer Center Hospital East, Kashiwa, Japan,

Abstract

Safety and efficacy of silibinin in patients with brain metastases after stereotactc radiosurgery: SUSTAIN trial.

Org: University of Florence, AOUC, Azienda Ospedaliera Universitaria Careggi, Istituto Fiorentino di Cura ed Assistenza, Istituto Fiorentino di Cura e Assistenza (IFCA),

Abstract

A matching-adjusted indirect treatment comparison of elranatamab in patients with triple-class exposed relapsed/refractory multiple myeloma: Comparisons with belantamab mafodotin, selinexor plus dexamethasone, and real-world physician’s choice of treatment.

Org: Pfizer Inc., London, United Kingdom, Cytelligen, San Diego, CA,

Abstract

Bortezomib-induced cardiotoxicity: Real-world data from a single-center.

Org: LSU Health Shreveport, Louisiana State University Shreveport, Feist-Weiller Cancer Center at LSUHSC-Shreveport, Louisiana State University (Shreveport) Program at Feist-Weiller Cancer Center,

Abstract

Single center experience of using Anakinra prophylactically at Day 0 to reduce CD19 CART toxicities.

Org: Augusta University Georgia Cancer Center, University of Illinois Urbana-Champaign, College of Medicine, University of the Philippines - Manila, Medical College of Georgia, Augusta, GA, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,

Abstract

Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.

Org: University of Chicago Medical Center, Chicago, IL, Center for Data Intensive Science at the University of Chicago, University of Chicago,

Abstract

Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.

Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center,

Abstract

Phase 3 RCT of dexamethasone versus placebo for chemotherapy induced fatigue in patients with advanced solid malignancies.

Org: Cancer Institute (WIA), Chennai, India,

Abstract

A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma.

Org: John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Hackensack University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian Health,

Abstract

A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.

Org: Cancer Institute of Jiangsu Province,

Abstract

Safety, tolerability, and quality of life (QoL) of single-agent plinabulin (Plin) for the prevention of docetaxel (Doc) chemotherapy (chemo)-induced neutropenia (CIN) in non-small cell lung cancer (NSCLC) patients (pts) from two randomized trials.

Org: Stanford Cancer Institute, BeyondSpring Pharmaceuticals, Inc.,

Abstract

Dexamethasone and exercise for cancer-related fatigue: A phase III randomized controlled trial.

Org: Tata Memorial Centre, Tata Memorial Hospital (HBNI), Tata Memorial Centre (HBNI),

Abstract

Comparing the time toxicity of cancer treatments in the CCTG LY.12 trial.

Org: University of Minnesota Masonic Cancer Center, Minneapolis, MN, Queen's University, Belfast, Princess Margaret - University Health Network, Canadian Cancer Trials Group, NCIC Clinical Trials Group,

Abstract

Integrating technology to support data management abstraction of adverse events (AE) and concomitant medications (ConMed) from the electronic health record (EHR) to sponsor electronic data capture (EDC) systems using design thinking (DT) methodology.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.

Abstract

ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).

Org: Valkyrie Clinical Trials, Inc, Rocky Mountain Cancer Centers, Millennium Oncology, Virginia Cancer Specialists, Genprex,

Abstract

External validation of venous thromboembolism risk prediction models in patients with multiple myeloma in a community setting: A retrospective cohort study.

Org: Saint Vincent Hospital Cancer Center Green Bay, University of Pittsburgh Medical Center Cancer Center, Saint Vincent Cancer and Wellness Center, Saint Vincent Hospital, Department of Hematology/Oncology, Internal Medicine, St. Vincent Hospital,

Abstract

Spectrum of germline pathogenic variants among patients with cancer in Mexico.

Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico, National Institute of Medical Sciences and Nutrition Salvador Zubirán, City of Hope National Medical Center, Latin American School of Oncology,

Abstract

A novel risk assessment metric for antimyeloma therapies and drug interactions.

Org: Kansas State University–Olathe, DATA Consortium, Computational Comparative Medicine, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy, Myeloma Program,

Abstract

Management and outcomes of advanced stage cardiac AL amyloidosis in the daratumumab era.

Org: University of California, San Diego Center for Advanced Laboratory Medicine,

Abstract

Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study.

Org: Cerner Enviza, Pfizer Inc., London, United Kingdom,

Abstract

Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience.

Org: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine,

Abstract

Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM).

Org: Queen Elizabeth II Health Sciences Centre and Dalhousie University, David Geffen School of Medicine at UCLA, Banner MD Anderson Cancer Center, Division of Hematology/Oncology, Columbia University, Clalit Health Services, Ha’Emek Medical Center,

Abstract

Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB.

Org: University of Arkansas for Medical Sciences (UAMS), Jordan University of Science and Technology, University of Arkansas for Medical Sciences Winthrop P. Rockefeller Institute, Myeloma Center, The University of Arkansas for Medical Sciences/Arkansas Children’s Hospital,

Abstract

Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.

Org: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Dublin, Ireland, Alexandra Hospital, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Alexandra Hospital, Athens, Greece,

Abstract

Outcomes with bendamustine lymphodepletion prior to brexucabtagene autoleucel for mantle cell lymphoma.

Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA,

Abstract

Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.

Org: Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, University Federico II, Cimitile, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST (IRCCS) s,

Abstract

Real-world analysis of D-RVd v. RVd at induction for newly diagnosed transplant eligible multiple myeloma patients.

Org: HealthTree Foundation, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT,

Abstract

Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment.

Org: Vanderbilt University Medical Center, Hematology Department, Hospital Universitari i Politècnic La Fe, CHU Nantes-Department of Hepato-Gastroenterology, University of North Carolina School of Medicine, University of Wisconsin Health,

Abstract

Racial differences in outcomes of patients with relapsed/refractory multiple myeloma treated with selinexor.

Org: Michigan State University, Karmanos Cancer Institute, McLaren Greater Lansing, Michigan State University College of Human Medicine, Michigan State University - College of Osteopathic Medicine,

Abstract

Incidence of second primary malignancies (SPMs) in patients with multiple myeloma (MM) receiving anti-CD38 monoclonal antibodies (mAbs): A systematic review and meta-analysis.

Org: Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, Massachusetts General Hospital, Boston, MA, USA, The University of Arizona, Tucson, AZ, Faculty of Health Sciences, Hamilton, ON, Canada,